美国食品药品监督管理局（FDA）已批准默沙东（Merck）的Keytruda®（帕博利珠单抗）及其复方制剂Keytruda Qlex™（帕博利珠单抗与透明质酸酶阿尔法-彭夫组合）联合紫杉醇，可选择性地加用贝伐珠单抗，作为特定成人患者的治疗方案。
该适应症针对的是PD-L1阳性（综合阳性评分CPS≥1）的铂类耐药卵巢癌患者，适用于二线或三线治疗。这一批准为这类难治性卵巢癌患者提供了新的免疫治疗选择。
美国食品药品监督管理局（FDA）已批准默沙东（Merck）的Keytruda®（帕博利珠单抗）及其复方制剂Keytruda Qlex™（帕博利珠单抗与透明质酸酶阿尔法-彭夫组合）联合紫杉醇，可选择性地加用贝伐珠单抗，作为特定成人患者的治疗方案。
该适应症针对的是PD-L1阳性（综合阳性评分CPS≥1）的铂类耐药卵巢癌患者，适用于二线或三线治疗。这一批准为这类难治性卵巢癌患者提供了新的免疫治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.